Results 11 to 20 of about 42,779 (160)

Serum Levels of Antibodies to Advanced Glycation End Products in Patients with Type 2 Diabetes Mellitus and Hypertension [PDF]

Folia Medica, 2020
Background and Aims: Proteins containing advanced glycation end products are highly immunogenic and anti-advanced glycation end products antibodies (anti-AGEs antibodies) are found in the sera of diabetics.Materials and methods: Enzyme-linked ...
Asparuh Nikolov, Alexander Blazhev, Maria Tzekova, Konstantin Kostov, Nikola Popovski   +4 more
doaj   +3 more sources

Soluble levels of receptor for advanced glycation endproducts and dysfunctional high-density lipoprotein in persons infected with human immunodeficiency virus: ACTG NWCS332. [PDF]

, 2018
The role of high-density lipoprotein (HDL) function and advanced glycation end products (AGEs) in HIV-related atherosclerotic cardiovascular disease (CVD) is unclear.
Aberg, Judith A, Currier, Judith S, Danoff, Ann, Kelesidis, Theodoros, Kendall, Michelle A, Schmidt, Ann Marie   +5 more
core   +1 more source

Synthesis and evaluation of naphthoic acid derivatives as fluorescent probes to screen advanced glycation end-products breakers [PDF]

, 2012
Advanced glycation end-products, namely AGEs, are involved in the pathogenesis of numerous diseases. If AGEs inhibitors are well-known, only few products are described as compounds able to destroy those deleterious products.
D. Seraphin, E. Levillain, F. Calard, L. Sanguinet, L. Séro, P. Richomme, S. Derbré   +6 more
core   +3 more sources

Advanced Glycation end products (AGEs) in food: focusing on Mediterranean pasta [PDF]

, 2015
5Advanced glycation end products, also known as glycotoxins, are a diverse group of highly oxidant compounds with pathogenic significance in aged-chronic disease, including diabetes, cardiovascular disease and neurodegenerative disease. They are produced
Abate, Giulia, Delbarba, Andrea, Marziano, Mariagrazia, Memo, Maurizio, Uberti, Daniela Letizia   +4 more
core   +1 more source

Advanced glycation end products modulate transcriptional regulation in mesangial cells [PDF]

, 1996
Advanced glycation end products modulate transcriptional regulation in mesangial cells. Advanced glycation end products (AGEs) stimulate synthesis of extracellular matrix (ECM) in a receptor-mediated manner on mesangial cells.
Iehara, Noriyuki, Takeoka, Hiroya, Yamada, Yoshihiko, Kita, Toru, Doi, Toshio   +4 more
core   +1 more source

Changes in non-enzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronate [PDF]

, 2009
Summary One year of high-dose bisphosphonate (BPs) therapy in dogs allowed the increased accumulation of advanced glycation end-products (AGEs) and reduced postyield work-to-fracture of the cortical bone matrix.
Allen, Matthew R., Burr, David B., Phipps, R, Tang, SY, Vashishth, Deepak   +4 more
core   +1 more source

The critical role of methylglyoxal and glyoxalase 1 in diabetic nephropathy [PDF]

, 2013
The discovery of increased formation of methylglyoxal (MG) by cell metabolism in high glucose concentration in vitro suggested possible relevance to diabetes and diabetes complications (1,2).
Rabbani, Naila, Thornalley, Paul J.
core   +1 more source

Estimation of Advanced Glycation end-Products in Patients of Vitiligo [PDF]

Egyptian Journal of Medical Research, 2022
The goal of this study is to detect a relationship between advanced glycation end-products and the pathogenesis of vitiligo in diseased patients as compared to normal control persons using Enzyme-Linked Immunosorbent Assay (ELISA) technique on tissue ...
Amany Ali, Mona Ahmed, Abd-El Aziz El- Rifaie   +2 more
doaj   +1 more source

Advanced glycoxidation and lipoxidation end products (AGEs and ALEs): an overview of their mechanisms of formation [PDF]

, 2013
Advanced lipoxidation end products (ALEs) and advanced glycation end products (AGEs) have a pathogenetic role in the development and progression of different oxidative-based diseases including diabetes, atherosclerosis, and neurological disorders.
A. Cipak, Abraham K, Abraham K, Adamiec J, Alary J, Aldini G, Amadori M, Andrewes P, Arntz D, Avzianova E, Balogh LM, Baumgart T, Baynes JW, Bechara EJH, Bein K, Beisswenger PJ, Biemel KM, Biemel KM, Biemel KM, Bondoc FY, Breyer V, Bunn HF, Butterfield DA, Callingham BA, Camel V, Cammerer B, Carmella SG, Casazza JP, Catala A, Cho SJ, Choi CH, Choudhary V, Ciulla MM, Collard F, Cooper R, Cooper RA, Cotham WE, Cui Q, D. De Maddis, Dai ZY, Davidek T, Davies SS, Degen J, Degenhardt TP, Del Rio D, Delpierre G, Dhar A, Dills WL, Doorn JA, Doureradjou P, Dunkerton J, Dyer DG, Eisner BH, Erbersdobler HF, Esterbauer H, Fan XJ, Franke S, Fu MX, Fu TM, Fujioka K, Furuhata A, G. Aldini, G. Vistoli, Garzon B, Geissler S, Gensberger S, Glomb MA, Glomb MA, Gobert J, Goh S-Y, Grandhee SK, Guéraud F, Hamada Y, Hartkopf J, Hayase F, Hellwig M, Henle T, Henle T, Henle T, Hermetter A, Heyns K, Hidalgo FJ, Hodge J, Hoff HF, Hollnagel A, HomokiFarkas P, Huber J, Iacobini C, Iijima K, Isbell H, Ishii T, Ishii T, Jadhav H, Jaganjac M, Jono T, Jung JY, Kalapos M, Kalapos MP, Kalapos MP, Karachalias N, Kielhorn J, Klopfer A, Krause R, Kroh LW, Kuiper HC, Kunkel HG, Kuntz S, Kurata T, Kurien BT, Lal S, Lange JN, Laroque D, Lederer MO, Li JL, Lin D, Linden T, Liu L, Liu ZF, Lo TWC, Long EK, LoPachin RM, LoPachin RM, Luevano-Contreras C, M. Carini, Maeshima T, Maillard L, Manini P, Mannervik B, Meade SJ, Mittelmaier S, Miyata S, Monnier VM, Montuschi P, Morales FJ, Munoz-Clares RA, N. Zarkovic, Nagaraj RH, Nagaraj RH, Namiki M, Nasiri R, Nasiri R, Nasiri R, Negre-Salvayre A, Nemet I, Nemet I, Nemet I, Niki E, Nishibori S, Niwa H, Niwa T, Niwa T, Nursten H, Obayashi H, Ortiz A, Ota M, Oya T, Pamplona R, Pamplona R, Pfeifer YV, Rabbani N, Ramasamy R, Reihl O, Reihl O, Requena JR, Rippe JM, Sakai M, Salomon RG, Schalkwijk CG, Schalkwijk CG, Schwarzenbolz U, Schwarzenbolz U, Sebekova K, Seiler N, Sell DR, Sell DR, Sell DR, Sell DR, Shangari N, Shibata T, Shipanova IN, Silva AMN, Sjoberg JS, Skovsted IC, Slatter DA, Slaughter JC, Spiteller P, Stevens JF, Sugiyama S, Suárez G, Szori M, Talhout R, Tessier F, Tessier FJ, Thornalley PJ, Thornalley PJ, Thornalley PJ, Thornalley PJ, Tsukushi S, Turk Z, Uchida K, Uchida K, Van Lancker F, Vander Jagt DL, Vander Jagt DL, Vedantham S, Wang HY, Wang TN, Wang Y, Wang Y, Wellsknecht KJ, Wellsknecht KJ, Westwood ME, Yamagishi S, Yang K, Yap FYT, Yin HY, Zeitsch K, Zeng JM, Zhang M, Zhu XC   +219 more
core   +1 more source

The Possible Mechanism of Advanced Glycation End Products (AGEs) for Alzheimer's Disease. [PDF]

PLoS ONE, 2015
Amyloid precursor protein (APP) has been modified by β and γ-secretase that cause amyloid deposits (plaques) in neuronal cells. Glyceraldhyde-derived AGEs has been identified as a major source of neurotoxicity in Alzheimer's disease (AD).
Shun-Yao Ko, Hshin-An Ko, Kuo-Hsiung Chu, Tzong-Ming Shieh, Tzong-Cherng Chi, Hong-I Chen, Weng-Cheng Chang, Shu-Shing Chang   +7 more
doaj   +1 more source